Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.41 |
| ▸ | CTSD | P07339 | 2/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.40 |
| ▸ | GLP1R | P43220 | 2/20 | 0.38 |
| ▸ | SCTR | P47872 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259072 | 0.93 | BACE1 (0.41) | BACE1CTSDBACE2 | |
| SCHEMBL7555807 | 0.91 | ENPEP (0.42) | BACE1CTSDGLP1R | |
| SCHEMBL30353795 | 0.90 | BACE1 (0.47) | BACE1GLP1R | |
| SCHEMBL30913884 | 0.88 | BACE1 (0.40) | BACE1CTSD | |
| SCHEMBL30913885 | 0.88 | BACE1 (0.40) | BACE1CTSD | |
| SCHEMBL29871022 | 0.87 | NOD1 (0.40) | — | |
| SCHEMBL29805325 | 0.85 | BACE1 (0.44) | BACE1CTSDBACE2GLP1RSCTR | |
| SCHEMBL31256972 | 0.85 | BACE1 (0.48) | BACE1CTSDBACE2 | |
| SCHEMBL31257083 | 0.85 | BACE1 (0.43) | BACE1CTSDBACE2GLP1RSCTR | |
| SCHEMBL30476106 | 0.84 | BACE1 (0.49) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599703-B2 | Hybrid heterogeneous hydrogel, manufacturing method and use as an in-situ non-degradable filler implant | NEUROBIOMAT (FR) | 2026-04-14 | — | — | US | disclosed |
| EP-4121133-B1 | HYBRID HETEROGENEOUS HYDROGEL, MANUFACTURING METHOD AND USE AS AN IN-SITU NON-DEGRADABLE FILLLER IMPLANT | NEUROBIOMAT (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-20230166005-A1 | HYBRID HETEROGENEOUS HYDROGEL, MANUFACTURING METHOD AND USE AS AN IN-SITU NON-DEGRADABLE FILLER IMPLANT | NEUROBIOMAT (FR) | 2023-06-01 | — | — | US | disclosed |
| EP-4121133-A1 | HYBRID HETEROGENEOUS HYDROGEL, MANUFACTURING METHOD AND USE AS AN IN-SITU NON-DEGRADABLE FILLLER IMPLANT | NEUROBIOMAT (FR) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599703-B2 | Hybrid heterogeneous hydrogel, manufacturing method and use as an in-situ non-degradable filler implant | CD44, MYB, HPGDS | BACE1 4857/4885CTSD 2474/4885BACE2 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.